What Is HCC Prognosis by Stage and Liver Function?

When doctors estimate life expectancy and prognosis for hepatocellular carcinoma (HCC), they look at a complete picture of your health, not just the tumor itself ^[1]. While HCC often develops in a damaged liver, this is not always the case ^[1]. Because of this, your prognosis is an individualized estimate based on three major, interacting domains: the size and spread of the cancer, how well your liver is functioning, and your overall physical strength ^[1][2][3]. Prognosis can also change over time based on how the tumor responds to treatment ^[1].

It is important to approach survival statistics found online with caution. Median survival means that half of a studied group lived longer than that time and half lived shorter; it is a population statistic, not a prediction of exactly how long you will live. Additionally, older statistics often included patients who received no treatment or were treated before the development of modern therapies ^[4]. Today, advances in targeted therapies (drugs that attack specific cancer cells) and immunotherapies (treatments that help your immune system fight the cancer) are improving outcomes, meaning many historical numbers no longer reflect current medical expectations ^[5][6].

The BCLC Staging System

Doctors most commonly use the Barcelona Clinic Liver Cancer (BCLC) staging system to guide treatment and estimate prognosis ^[1]. This system is unique because it combines tumor characteristics, liver health, and daily physical functioning ^[1][3].

The stages are generally defined as:

• Stage 0 (Very Early): A single tumor 2 centimeters or smaller ^[1]. The liver functions normally, and the patient’s performance status is fully active (ECOG 0) ^[1].
• Stage A (Early): A single tumor of any size, or up to three tumors that are each 3 centimeters or smaller ^[1]. The liver still functions normally, and the patient is fully active ^[1].
  • Prognosis Context: Patients in Stages 0 and A often qualify for treatments intended to cure the cancer, such as surgery or tumor ablation. For example, in modern cohorts of highly selected patients undergoing curative-intent surgical removal of the tumor (resection), researchers have observed 5-year survival rates (the percentage of patients alive after five years) of approximately 80% ^[7].
• Stage B (Intermediate): Multiple tumors confined to the liver ^[1]. The liver functions well, and the patient is fully active ^[1]. Survival times vary widely in this stage depending on the exact tumor burden and specific treatments used, with some patient subgroups achieving median survivals from one to over four years ^[8][9].
• Stage C (Advanced): The cancer has grown into blood vessels within the liver (vascular invasion) or spread to other organs (extrahepatic spread) ^[1]. This stage also includes patients with tumors confined to the liver but who are experiencing mild cancer-related symptoms ^[1][10].
  • Prognosis Context: Survival in Stage C has improved significantly. In the major IMbrave150 clinical trial, selected patients receiving a first-line immunotherapy combination (atezolizumab and bevacizumab) achieved a median survival of 19.2 months ^[5]. Another modern trial using camrelizumab and rivoceranib reported a median survival of over 22 months ^[6]. These represent outcomes for eligible trial participants, not a universal guarantee.
• Stage D (End-Stage): The patient has severe liver failure and is not a candidate for a liver transplant, OR the patient is physically too weak to undergo active cancer treatments ^[1][11].
  • Note: Having severe liver disease does not automatically mean the cancer is terminal. Some patients with failing livers may still be evaluated for a liver transplant ^[1]. For those in Stage D, supportive and palliative care (focusing on symptom relief and quality of life) becomes the primary focus, though palliative care can and should be integrated alongside active cancer treatment at any stage ^[11].

The Role of Liver Function

Your liver’s ability to clear toxins and make proteins is just as critical as the cancer stage ^[2]. Doctors measure this using two main scoring systems:

• Child-Pugh Score: This traditional system grades your liver as Class A (working well), Class B (moderate damage), or Class C (severe damage) ^[2]. It uses blood tests and physical signs like ascites (fluid buildup in the belly) and hepatic encephalopathy (confusion caused by toxins reaching the brain) ^[2].
• ALBI Grade: This newer, objective system uses only two blood tests (albumin and bilirubin) to assess liver health ^[2]. ALBI helps doctors identify small differences in liver function, especially among patients who appear healthy in the Child-Pugh A category ^[12].

These scores do not determine prognosis on their own, but they help doctors understand which treatments your liver can safely handle ^[2][12].

Physical Performance Status

Your overall strength is evaluated using the ECOG Performance Status scale ^[13]. This measures how much the disease limits your daily activities, ranging from 0 (fully active) to 4 (completely bedbound). A declining performance status is a strong predictor of a shorter survival time and helps doctors decide if systemic (full-body) treatments are safe for you ^[13].

Why Context Matters for Statistics

Historical registry data can be frightening. For instance, a study of untreated patients diagnosed between 2004 and 2011 showed median survival times of just 13.4 months for early-stage disease and 3.4 months for advanced disease ^[4]. However, these numbers represent an older era and untreated individuals. While registry statistics remain useful for population-level counseling, your doctor’s individualized assessment—taking into account your specific tumor burden, liver health, physical strength, and response to modern therapies—will always be the most accurate reflection of your prognosis.